Name: Supernus Pharmaceuticals, Inc. (SUPN) Financial Statements
Creator: FinSpry

Supernus Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Supernus Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
Revenue & Gross Profit
Revenue	661.82	607.52	667.24	579.78	520.40	392.76	408.90
Cost of Revenue	77.91	83.78	87.22	75.06	52.46	16.66	15.36
Gross Profit	583.91	523.74	580.02	504.71	467.94	376.10	393.54
Operating Expenses
Research & Development	108.80	91.59	74.55	90.47	75.96	69.10	89.21
Selling, General & Administrative	321.58	336.36	377.22	304.76	200.68	153.25	154.70
Operating Expenses	508.36	510.34	534.40	425.22	292.34	227.52	249.10
Operating Income	75.56	-5.27	45.61	86.03	173.70	148.57	144.44
Other Income/Expense
Interest Income	16.20	10.45	21.69	10.22	14.35	0.00	13.84
Interest Expense	0.00	-2.42	-7.07	-23.42	-23.75	0.00	18.11
Other Income/Expense	6.11	8.22	21.68	6.32	6.95	1.08	0.00
Income
Income Before Tax	97.87	2.77	60.74	73.18	168.65	147.49	140.18
Income Tax Expense	24.01	1.45	0.03	19.75	41.70	34.43	29.18
Net Income	73.87	1.32	60.71	53.42	126.95	113.06	110.99
Net Income - Continuous Operations	73.87	1.32	60.71	53.42	0.00	0.00	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	178.28	89.48	131.16	129.19	210.54	169.85	165.35
EBIT	97.87	4.09	45.61	96.60	192.40	147.49	158.29
Depreciation & Amortization	77.98	82.39	85.54	29.99	15.70	5.18	5.19
Earnings Per Share
Basic EPS	1.00	-	1.00	1.00	2.00	2.00	2.00
Diluted EPS	1.00	-	1.00	1.00	2.00	2.00	2.00
Basic Shares Outstanding	55.10	54.54	53.67	53.10	52.62	52.41	51.99
Diluted Shares Outstanding	55.96	55.51	61.68	54.36	53.69	53.82	54.10